ReviewAdvances in therapy2018
A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies.
Review in Advances in therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 4 syntheses or guidelines pooled it, 211 citations in OpenAlex.
- Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis.World journal of gastroenterology · 2023Pooled it
- Nutraceuticals in the Modulation of the Intestinal Microbiota: Current Status and Future Directions.Frontiers in pharmacology · 2022Pooled it
- Dietary Patterns and Interventions to Alleviate Chronic Pain.Nutrients · 2020Pooled it
- Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis.Medicine · 2019Pooled it
- Trial
- A Comprehensive Self-Management Program With Diet Education Does Not Alter Microbiome Characteristics in Women With Irritable Bowel Syndrome.Biological research for nursing · 2021Trial
- Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial.BMJ open gastroenterology · 2020Trial
- Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.BMC gastroenterology · 2020Trial
- Improved gastrointestinal health for irritable bowel syndrome with metagenome-guided interventions.Precision clinical medicine · 2020Trial
- A prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of SNZ TriBac, a three-strain Bacillus probiotic blend for undiagnosed gastrointestinal discomfort.International journal of colorectal disease · 2019Trial
- Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults.Scientific reports · 2019Trial
- Familial Patterns of Oral-Gut Dysbiosis and Systemic Markers in Periodontitis.Journal of clinical periodontology · 2026Article
- Ultra-Processed Food Consumption and Irritable Bowel Syndrome: Current Evidence and Clinical Implications.Nutrients · 2025Review
- Carrot Rhamnogalacturonan-I Supplementation Shapes Gut Microbiota and Immune Responses: A Randomised Trial in Healthy Adults.Microorganisms · 2025Article
- The Microecological-Immune Axis in Pediatric Allergic Diseases: Imbalance Mechanisms and Regulatory Interventions.Nutrients · 2025Review
- The potential therapeutic approaches targeting gut health in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a narrative review.Journal of translational medicine · 2025Review
- A Probiotic Mixture ofInternational journal of molecular sciences · 2025Article
- An 8-Week Course of Bifidobacterium longum 35624Probiotics and antimicrobial proteins · 2025Observational
- Microbiome: A Key Regulator of Body-Brain Interactions.Advances in experimental medicine and biology · 2025Review
- The Role of the Gut Microbiota in Individuals with Irritable Bowel Syndrome: A Scoping Review.Medicina (Kaunas, Lithuania) · 2024Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS), one of the most frequent digestive disorders, is characterized by chronic and recurrent abdominal pain and altered bowel habit. The origin seems to be multifactorial and is still not well defined for the different subtypes. Genetic, epigenetic and sex-related modifications of the functioning of the nervous and immune-endocrine supersystems and regulation of brain-gut physiology and bile acid production and absorption are certainly involved. Acquired predisposition may act in conjunction with infectious, toxic, dietary and life event-related factors to enhance epithelial permeability and elicit mucosal microinflammation, immune activation and dysbiosis. Notably, strong evidence supports the role of bacterial, viral and parasitic infections in triggering IBS, and targeting microbiota seems promising in view of the positive response to microbiota-related therapies in some patients. However, the lack of highly predictive diagnostic biomarkers and the complexity and heterogeneity of IBS patients make management difficult and unsatisfactory in many cases, reducing patient health-related quality of life and increasing the sanitary burden. This article reviews specific alterations and interventions targeting the gut microbiota in IBS, including prebiotics, probiotics, synbiotics, non-absorbable antibiotics, diets, fecal transplantation and other potential future approaches useful for the diagnosis, prevention and treatment of IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.